.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Genetic medicine is entering a new era with the development of lipid nanoparticles (LNPs) for precision delivery. Specifically, bone marrow RNA therapeutics offer a transformative approach to treating complex blood disorders like leukemia. However, delivering these molecules effectively remains a significant challenge due to the body's natural clearance mechanisms. Consequently, researchers are designing novel systems to overcome physiological barriers and improve clinical outcomes.
Current LNP formulations typically accumulate in the liver, which limits their effectiveness for extrahepatic diseases. Notably, the mononuclear phagocyte system and rapid systemic clearance hinder organ-specific accumulation. Therefore, developing specialized particles that can bypass these obstacles is essential for medical advancement. Researchers must also address endosomal escape to ensure the RNA payload functions correctly within target cells.
Scientists are exploring both passive and active targeting methods to improve organ specificity. Passive strategies involve modifying the size and surface charge of the nanoparticle to increase circulation time. Additionally, active targeting uses specific ligands, such as those for Very-Late Antigen-4 (VLA-4), to direct LNPs to hematopoietic stem cells. Consequently, these innovations ensure that therapeutic RNA reaches its intended destination within the marrow. Furthermore, emerging preclinical models help refine these delivery vehicles before human trials begin.
These next-generation delivery systems could revolutionize the treatment of hematological malignancies. Furthermore, they provide a robust platform for advanced regenerative therapies. In addition, the ability to transfect hard-to-reach blood cells opens doors for personalized medicine in oncology and hematology. Ultimately, these advances establish a framework for treating various bone marrow-associated diseases more effectively.
LNPs often face rapid clearance by the liver and the mononuclear phagocyte system. These physiological barriers prevent a sufficient concentration of the therapeutic RNA from reaching extrahepatic tissues like the bone marrow.
Active targeting involves attaching specific ligands to the nanoparticle surface that bind to receptors on target cells. This process significantly increases cellular specificity and improves the uptake of RNA in hematopoietic progenitor cells.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Casimiro LDM et al. Lipid nanoparticles for bone marrow-targeted RNA therapeutics. J Nanobiotechnology. 2026 Apr 27. doi: 10.1186/s12951-026-04423-0. PMID: 42045944.
Parayath NN et al. Increased Bone Marrow Uptake and Accumulation of Very-Late Antigen-4 Targeted Lipid Nanoparticles. Front Pharmacol. 2020; 11: 603. doi: 10.3389/fphar.2020.00603.
Verma S et al. Lipid Nanoparticles for RNA Therapeutics: Recent Advances and Future Perspectives. J Chem Health Risks. 2024; 14(2): 3885-3894.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
This review explores lipid nanoparticle delivery to the bone marrow, highlighting challenges and targeting strategies for hematological malignancies....
2 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
